Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Sitagliptin Exerts an Antinflammatory Action

Open access
Makdissi, Antoine, Ghanim, Husam, Vora, Mehul, Green, Kelly, Abuaysheh, Sanaa, Chaudhuri, Ajay, Dhindsa, Sandeep, Dandona, Paresh·2012·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades the incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, and thus, sitagliptin increases their bioavailability. The stimulation of insulin and the suppression of glucagon secretion that follow exert a glucose lowering effect and hence its use as an antidiabetic drug. Because DPP-IV is expressed as CD26 on cell membranes and because CD26 mediates proinflammatory signals, we hypothesized that sitagliptin may exert an antiinflammatory effect. PATIENTS AND METHODS: Twenty-two patients with type 2 diabetes were randomized to receive either 100 mg daily of sitagliptin or placebo for 12 wk. Fasting blood samples were obtained at baseline and at 2, 4, and 6 hours after a single dose of sitagliptin and at 2, 4, 8, and 12 wk of treatment. RESULTS: Glycosylated hemoglobin fell significantly from 7.6 ± 0.4 to 6.9 ± 3% in patients treated with sitagliptin. Fasting glucagon-like peptide-1 concentrations increased significantly, whereas the mRNA expression in mononuclear cell of CD26, the proinflammatory cytokine, TNFα, the receptor for endotoxin, Toll-like receptor (TLR)-4, TLR-2, and proinflammatory kinases, c-Jun N-terminal kinase-1 and inhibitory-κB kinase (IKKβ), and that of the chemokine receptor CCR-2 fell significantly after 12 wk of sitagliptin. TLR-2, IKKβ, CCR-2, and CD26 expression and nuclear factor-κB binding also fell after a single dose of sitagliptin. There was a fall in protein expression of c-Jun N-terminal kinase-1, IKKβ, and TLR-4 and in plasma concentrations of C-reactive protein, IL-6, and free fatty acids after 12 wk of sitagliptin. CONCLUSIONS: These effects are consistent with a potent and rapid antiinflammatory effect of sitagliptin and may potentially contribute to the inhibition of atherosclerosis. The suppression of CD26 expression suggests that sitagliptin may inhibit the synthesis of DPP-IV in addition to inhibiting its action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-1544

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 14

  1. Herman, 2005, Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses., Clin Pharmacol Ther, 78, 675, 10.1016/j.clpt.2005.09.002 · DOI · Paper page
  2. Holz, 2003, Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus., Curr Med Chem, 10, 2471, 10.2174/0929867033456648 · DOI
  3. Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes., Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
  4. Reinhold, 2008, DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis., Front Biosci, 13, 2356, 10.2741/2849 · DOI
  5. Preller, 2007, TGF-β1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26., J Immunol, 178, 4632, 10.4049/jimmunol.178.7.4632 · DOI
  6. Dandona, 2001, Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?, J Clin Endocrinol Metab, 86, 3257
  7. He, 2007, The role of the receptor for advanced glycation end-products in lung fibrosis., Am J Physiol Lung Cell Mol Physiol, 293, L1427, 10.1152/ajplung.00075.2007 · DOI · Paper page
  8. Tripathy, 2003, Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects., Diabetes, 52, 2882, 10.2337/diabetes.52.12.2882 · DOI · Paper page
  9. Hallman, 2001, Toll-like receptors as sensors of pathogens., Pediatr Res, 50, 315, 10.1203/00006450-200109000-00004 · DOI
  10. Crowe, 2001, Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression., Neoplasia, 3, 27, 10.1038/sj.neo.7900135 · DOI
  11. Bennett, 2003, JNK: a new therapeutic target for diabetes., Curr Opin Pharmacol, 3, 420, 10.1016/S1471-4892(03)00068-7 · DOI
  12. Ehses, 2010, Toll-like receptor 2-deficient mice are protected from insulin resistance and β cell dysfunction induced by a high-fat diet., Diabetologia, 53, 1795, 10.1007/s00125-010-1747-3 · DOI · Paper page
  13. Monami, 2011, Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials., Curr Med Res Opin, 27, 57, 10.1185/03007995.2011.602964 · DOI · Paper page
  14. Viswanathan, 2007, Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin., Endocr Pract, 13, 444, 10.4158/EP.13.5.444 · DOI

Cited by

See all 241

Metadata

Authors
Makdissi, A., Ghanim, H., Vora, M., Green, K., Abuaysheh, S., Chaudhuri, A., Dhindsa, S., & Dandona, P.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-09-01
Volume
97
Issue
9
Pages
3333-3341
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2114531479
Cited by
241
References
8
FWCI
14.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sitagliptin Exerts an Antinflammatory Action. https://app.cochat.ai/papers/10.1210/jc.2012-1544
The paper
Makdissi, A., Ghanim, H., Vora, M., Green, K., Abuaysheh, S., Chaudhuri, A., Dhindsa, S., & Dandona, P. (2012). Sitagliptin Exerts an Antinflammatory Action. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-1544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.